Virpax Completes FDA Required Preclinical Toxicology Studies For Its Licensed Molecular Envelope Technology

Feb 15, 2023

admin2023-02-16T20:02:32-05:00February 15th, 2023|Media|

NASDAQ: VRPX

Corporate Headquarters
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312

Phone 610.727.4597
Email info@virpaxpharma.com

NASDAQ: VRPX

Corporate Headquarters
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312

Phone 610.727.4597
Email info@virpaxpharma.com